Zydus' Nesher Pharmaceuticals receives USFDA approval for ADHD drug

Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended- Release Capsules (US RLD ADDERALL XR), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 60 mg.

The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) which is a brain disorder characterized by an ongoing pattern of inattention and, or hyperactivityimpulsivity that interferes with functioning or development. It will be manufactured at Nesher Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.

Powered by Capital Market - Live News